Form 4: Lexeo Therapeutics Executive Sells Shares to Cover Tax Obligations

Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, sold 367 shares of common stock on May 16, 2025, to cover tax obligations related to the release of restricted stock units.

Summary

• On May 16, 2025, Sandi See Tai, the Chief Development Officer of Lexeo Therapeutics, sold 367 shares of the company's common stock.
• The sale was executed at a price of $2.774 per share.
• This transaction was conducted to cover tax obligations arising from the release of restricted stock units (RSUs).
• Following the transaction, Sandi See Tai beneficially owns 59,242 shares, which includes 50,178 RSUs.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't convey any particularly positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

Sales of shares to cover tax obligations upon the vesting of restricted stock units are a common practice among corporate executives. This transaction reflects a standard financial planning activity and doesn't necessarily indicate a change in the executive's confidence in the company's future prospects.

Comparison to Industry Standards

• Executive stock sales for tax purposes are common across the pharmaceutical and biotech industries.
• Similar transactions are frequently observed at companies like Amgen, Biogen, and Gilead Sciences, where executives routinely sell shares to cover tax liabilities associated with equity compensation.
• The number of shares sold and the price per share are within typical ranges for such transactions.

Key Dates

Keywords

Lexeo Therapeutics, Sandi See Tai, Chief Development Officer, Form 4, Stock Sale, Restricted Stock Units, Tax Obligations, LXEO